SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
SpyGlass Pharma, Inc. Common StockNASDAQ: SGP
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA of -$13.5M in Q1 FY2026
Q1 FY2026 EBITDA was -$13.5M.
What to watch
Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$13.5M-9.4% QoQ
- Last fiscal yearDec 2025
- -$39.26M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | — | +100.0% | — |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (39.26M) USD
- Year-over-year change
- —
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (39.26M) | — |
EBITDA vs competitors
How SGP compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $2.78B USD | +3.6% | +12.8% | 25.4% | |
| LTM Jun 2026 | $742M USD | +61.3% | -3.6% | 13.9% | |
| LTM Apr 2026 | -$4.11M USD | +87.8% | — | 1.4% | |
| LTM Mar 2026 | -$31.68M USD | +27.7% | — | 39.8% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | -$39.26M USD | — | — | — |
| LTM Mar 2026 | -$43.24M USD | -86.4% | — | 33.9% | |
| LTM Mar 2026 | -CHF 94.13M CHF | +7.5% | — | 18676.3% | |
| LTM Jun 2026 | -$140.99M USD | -195.0% | — | 23.0% | |
| LTM Mar 2026 | -$260.06M USD | -79.4% | — | 3415.1% | |
| LTM Mar 2026 | -$274.24M USD | -55.5% | — | 527.0% | |
| Peer median (excluding SGP) | — | +3.6% | +4.6% | 33.9% | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 612K |
| Gross Profit | (612K) |
| Gross Margin | — |
| Research & Development | 28.64M |
| Selling, General & Admin | 12.2M |
| Operating Expenses | 40.84M |
| Depreciation & Amortization | 612K |
| EBITDA | (39.26M) |
| EBITDA Margin | — |
| Operating Income | (41.45M) |
| Operating Margin | — |
| Interest Income | 3.11M |
| Interest Expense | 0 |
| Other Income / Expenses | 1.58M |
| Income Before Tax | (39.87M) |
| Pre-Tax Margin | — |
| Income Tax Expense | 0 |
| Net Income | (39.87M) |
| Net Margin | — |
| EPS (Basic) | (1.19) |
| EPS (Diluted) | (1.19) |
| Weighted Avg Shares | 33.43M |
| Weighted Avg Shares (Diluted) | 33.43M |
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.